Evidence map›Paper›PMID 38045314›Full record

ArticleResearch square2023

Automatic renal carcinoma biopsy guidance using forward-viewing endoscopic optical coherence tomography and deep learning.

Qinggong Tang, Chen Wang, Haoyang Cui, Qinghao Zhang, Paul Calle, Yuyang Yan, Feng Yan, Kar-Ming Fung, Sanjay Patel, Zhongxin Yu and 3 more

Open access · greenAbstract readPreprint
In one paragraph

Article in Research square, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Qinggong Tang
Haoyang Cui
Qinghao Zhang
Yuyang Yan
Feng Yan
Kar-Ming Fung
Sanjay Patel
Zhongxin Yu
Sean Duguay
William Vanlandingham
Chongle Pan

Funding

Tracking and Evaluation CoreU54GM104938 · NIGMS · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI Valerie Williams · 2013 to 2026
$68.2M
Tissue Pathology Shared ResourceP30CA225520 · NCI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI ROBERT S. MANNEL · 2018 to 2026
$27.1M
TUMOR RESISTANCE MECHANISMS TO ANTI-VEGF THERAPY IN PROSTATE CANCER (Sukyung Woo)P20GM103639 · NIGMS · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI DHANASEKARAN, DANNY N. · 2012 to 2022
$21.3M
Use of 3D Quantitative Optical Methods to Optimize Mebendazole Treatment of Ovarian CancerP20GM135009 · NIGMS · UNIVERSITY OF OKLAHOMA · PI Javier Antonio Jo · 2022 to 2026
$13.6M
Automatic Wide-Field Optical Coherence Tomography for Assessment of Transplant Kidney ViabilityR01DK133717 · NIDDK · UNIVERSITY OF MASSACHUSETTS AMHERST · PI POTTER, STEVEN, TANG, QINGGONG · 2022 to 2025
$2.5M
NCI NIH HHS P30 CA225520NIDDK NIH HHS R01 DK133717NIGMS NIH HHS P20 GM103639NIGMS NIH HHS P20 GM135009NIGMS NIH HHS U54 GM104938
6 · The paper itself

Abstract

Percutaneous renal biopsy (PRB) is commonly used for kidney cancer diagnosis. However, current PRB remains challenging in sampling accuracy. This study introduces a forward-viewing optical coherence tomography (OCT) probe for differentiating tumor and normal tissues, aiming at precise PRB guidance. Five human kidneys and renal carcinoma samples were used to evaluate the performance of our probe. Based on their distinct OCT imaging features, tumor and normal renal tissues can be accurately distinguished. We examined the attenuation coefficient for tissue classification and achieved 98.19% tumor recognition accuracy, but underperformed for distinguishing normal tissues. We further developed convolutional neural networks (CNN) and evaluated two CNN architectures: ResNet50 and InceptionV3, yielding 99.51% and 99.48% accuracies for tumor recognition, and over 98.90% for normal tissues recognition. In conclusion, combining OCT and CNN significantly enhanced the PRB guidance, offering a promising guidance technology for improved kidney cancer diagnosis.

Indexed as

Deep learningEndoscopeOptical coherence tomographyRenal cancer diagnosisSurgical Guidance

Identifiers

PMID38045314
PMCPMC10690309
OpenAlexW4388933821

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.